AbbVie Inc
I · Analyse IA
En bref
AbbVie researches, develops, and sells prescription medicines across multiple therapeutic areas. Their biggest focus is immunology drugs (like Skyrizi and Rinvoq) that treat autoimmune diseases, along with cancer treatments (Imbruvica, Venclexta), neuroscience medications (Vraylar, Botox, migraine drugs), and aesthetics products (facial injectables and skincare) [Yahoo Finance]. The company also sells eye care products and treatments for digestive conditions.
AbbVie is a large pharmaceutical company headquartered in Illinois that develops and sells medicines for serious diseases including autoimmune conditions, cancer, neurological disorders, and eye diseases [Yahoo Finance]. The company spun off from Abbott Laboratories in 2013 and now employs 57 000 people worldwide, generating $61,2 billion in annual revenue [Yahoo Finance]. AbbVie is successfully transitioning away from its former blockbuster drug Humira by growing newer products like Skyrizi, Rinvoq, and neuroscience treatments [Yahoo Finance].
AbbVie is financially healthy with strong cash generation, though it carries moderate debt and trades at an unusually high valuation [Yahoo Finance].
Score Sentinellis
7,4/10
Préoccupations modérées
Capitalisation boursière
$377,7B
Chiffre d'affaires (12 mois)
$61,2B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
6 articles · classés par pertinence
- Macro2026-05-19
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks
- Macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- Macro2026-05-19
Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer
Yahoo Finance
- Macro2026-05-19
2 Reasons to Like ABBV and 1 to Stay Skeptical
Yahoo Finance
- Macro2026-05-18
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
Yahoo Finance
- Macro2026-05-18
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth
Yahoo Finance
Premium · gratuit avec tout compte
AbbVie generates about half its revenue from immunology treatments, creating significant concentration risk if this single therapeutic area faces competitive pressure or regulatory challenges [Yahoo Finance]
Risques
4
Opportunités
6
Signaux d'alerte
2
Direction
10
11 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de AbbVie Inc
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 6 opportunités et 2 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?